首页> 美国卫生研究院文献>Experimental Molecular Medicine >Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer
【2h】

Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer

机译:评价头颈癌患者循环miRNA qPCR研究中的几种方法学挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Circulating microRNAs (ci-miRNAs) in blood have emerged as promising diagnostic, prognostic and predictive biomarkers in cancer. Many clinical studies currently incorporate studies that assess ci-miRNAs. Validation of the clinical significance of candidate biomarker miRNAs has proven to be difficult, potentially resulting from vast discrepancies in the detection methodology as well as biological variability. In the current study, the influence of several methodological factors on ci-miRNA detection was evaluated as well as short-term biological variability in patients with head and neck cancer. RNA was isolated from 124 serum and plasma samples originating from patients with head and neck cancer and healthy volunteers. The miRNA levels were measured using RT-qPCR and the influence of pre-analytical factors, different normalization strategies and temporal reproducibility was assessed. RNA carriers improved ci-miRNA detection in serum and plasma specimens. A prolonged pre-processing time correlated with an increased hemolytic index in serum samples only. Hemolysis differentially affected the detection of individual miRNAs. Optimal normalization was achieved using the averaged detection values of spike-in cel-miR-39-3p and endogenous miR-16-5p. Comparing biological replicates from patients with head and neck cancer, the intra-individual miRNA levels were relatively stable (average interval 7 days). Differences in the ci-miRNA detection methodology and limitations of currently used technologies can greatly affect the results and may explain inconsistent outcomes between studies. Prior to the implementation of ci-miRNAs as useful clinical biomarkers, further advances in the standardization of the detection methodology and reduction of technical variability are needed.
机译:血液中的循环microRNA(ci-miRNA)已成为癌症中有希望的诊断,预后和预测性生物标志物。当前,许多临床研究都纳入了评估ci-miRNA的研究。已证明很难验证候选生物标志物miRNA的临床意义,这可能是由于检测方法和生物学变异性方面的巨大差异所致。在当前的研究中,评估了几种方法学因素对ci-miRNA检测的影响以及头颈癌患者的短期生物学变异性。从头颈部癌患者和健康志愿者的124个血清和血浆样品中分离出RNA。使用RT-qPCR测量miRNA的水平,并评估分析前因素,不同的归一化策略和时间可重复性的影响。 RNA载体改善了血清和血浆标本中ci-miRNA的检测。延长的预处理时间仅与血清样品中的溶血指数增加相关。溶血有区别地影响单个miRNA的检测。使用cel-miR-39-3p和内源性miR-16-5p的平均检测值可以实现最佳归一化。比较头颈癌患者的生物学复制,个体内miRNA水平相对稳定(平均间隔7天)。 ci-miRNA检测方法的差异和当前使用技术的局限性会极大地影响结果,并可能解释研究之间的不一致结果。在将ci-miRNA用作有用的临床生物标记之前,需要在检测方法的标准化和降低技术变异性方面取得进一步进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号